Evidence-Based Reviews

Time to retire haloperidol?

Author and Disclosure Information

 

References

Ketamine. In recent years, ketamine has been used to treat acute agitation within or en route to the ED. Preliminary observational studies support ketamine’s efficacy when administered via IV or IM routes,76 with more rapid symptomatic improvement compared with haloperidol, lorazepam, or midazolam alone.77 Reported adverse effects of ketamine include dissociation, psychotic exacerbation, and respiratory depression,76 although 1 small naturalistic study found no evidence of exacerbation of psychotic or other psychiatric symptoms.78 An ongoing RCT is comparing IM ketamine, 5 mg/kg, to combined IM haloperidol, 5 mg, and midazolam, 5 mg.79 Although various ketamine formulations are increasingly being used in psychiatry, active psychosis is generally regarded as a contraindication. It is premature to recommend parenteral ketamine administration for agitation within most psychiatric settings until more research on safety has been completed.

Haloperidol, or something else? Practical considerations

Consider the following factors when deciding whether to use haloperidol or one of its alternatives:

Limitations of the evidence. Modern clinical trials requiring informed consent often do not include the kind of severe agitation that clinicians encounter in acute psychiatric, emergency, or forensic settings. In addition, standard interventions, such as 3-medication haloperidol “cocktails,” have not been evaluated in clinical trials. Clinicians are therefore often in the dark about optimal evidence-based practices.

Treatment goals. Psychiatric agitation has many causes, with a range of severity that warrants a commensurate range of responses. Protocols for managing acute agitation should include graded interventions that begin with nonpharmacologic interventions and voluntary oral medications, and move to involuntary IM medications when necessary.

While treatment guidelines clearly recommend against IM medications as “chemical restraint” with a goal of sedating a patient until he/she is unconscious,3,51 such outcomes are nonetheless often sought by staff who are concerned about the risk of injuries during a behavioral emergency. In such instances, the risks of violence towards patients and staff may outweigh concerns about adverse effects in a risk-benefit analysis. Consequently, clinicians may be prone to “skip over” graded interventions because they assume they “won’t work” in favor of administering involuntary multiple-medication haloperidol “cocktails” despite risks of excess sedation, EPS, and cardiotoxicity. Treatment settings should critically evaluate such biased preferences, with a goal of developing tailored, evidence-based strategies that maximize benefits while minimizing excess sedation and other untoward adverse effects, with an eye towards promoting better overall patient care and reducing length of stay.42,43,80

Continue to: Limitations of available medications

Pages

Recommended Reading

Coronavirus on the inpatient unit: A new challenge for psychiatry
MDedge Psychiatry
Psychiatric patients and pandemics
MDedge Psychiatry
Does your patient have the right to refuse medications?
MDedge Psychiatry
The psychiatric clinic of the future
MDedge Psychiatry
Command hallucinations, but is it really psychosis?
MDedge Psychiatry
Is psychosis toxic to the brain?
MDedge Psychiatry
The ABCDs of treating tardive dyskinesia
MDedge Psychiatry
First-in-class schizophrenia drug safe, effective, durable
MDedge Psychiatry
Drive-up pharmacotherapy during the COVID-19 pandemic
MDedge Psychiatry
Anti-NMDAR encephalitis or primary psychiatric disorder?
MDedge Psychiatry